Wednesday, July 16, 2025 7/16/2025

Development of a Vaccine for the Prevention of Pulmonary Aspergillosis

Award Number: R44AI115828
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2015
PERIOD OF PERFORMANCE END DATE: 12/31/2019

Group Awards By:

View Award Description

Development of a Vaccine for the Prevention of Pulmonary Aspergillosis - Project Summary The principal objective of this project is to develop a VesiVax® vaccine against Aspergillus fumigatus. The studies proposed in this SBIR Phase II application will be focused on continuing the development of a lead candidate VesiVax® vaccine containing recombinantly engineered antigens corresponding to Aspf3 and Aspf9. In the SBIR Phase I studies, we evaluated VesiVax® vaccine candidates in a clinically relevant animal model for the ability to protect against a pulmonary Aspergillus challenge. From the SBIR Phase I studies, the most effective VesiVax® vaccine candidate was identified and selected for advancement to clinical evaluation and development of a commercial product. In the proposed SBIR Phase II studies, our product development and commercialization efforts will be focused on using the VesiVax® vaccine to prevent or ameliorate disease in the primary patient population, immunocompromised hosts such as those individuals undergoing a solid organ transplant, bone marrow transplant or cancer chemotherapy. In these patients, the opportunity exists to immunize the patient prior to the onset of immunosuppression, with the goal that the acquired resistance from the vaccine can carry over through the course of the immunosuppression, thus reducing patient mortality and infection with Aspergillus.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	MOLECULAR EXPRESS INC	2630 HOMESTEAD PLACE	RANCHO DOMINGUEZ	CA	90220	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	4/14/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $497,338 )
2018	2018	MOLECULAR EXPRESS INC	2630 HOMESTEAD PLACE	RANCHO DOMINGUEZ	CA	90220	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	6/26/2018	NON-COMPETING CONTINUATION	$497,338
														Subtotal = $497,338

Issue Date FY: 2017 ( Subtotal = $934,456 )
2017	2017	MOLECULAR EXPRESS INC	2630 HOMESTEAD PLACE	RANCHO DOMINGUEZ	CA	90220	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	6/28/2017	COMPETING CONTINUATION	$934,456
														Subtotal = $934,456

Grand Total All Awards = $1,431,794

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Vaccine for the Prevention of Pulmonary Aspergillosis

Award Number: R44AI115828

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2015

PERIOD OF PERFORMANCE END DATE: 12/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer